These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 27595758)
1. Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis. Kobayashi T; Niioka T; Miura M; Takahashi N Ann Hematol; 2016 Dec; 95(12):2087-2088. PubMed ID: 27595758 [No Abstract] [Full Text] [Related]
2. LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients. Shu C; Zeng T; Gao S; Xia T; Huang L; Zhang F; Chen W J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():111-119. PubMed ID: 27336703 [TBL] [Abstract][Full Text] [Related]
3. Thalidomide in patients with multiple myeloma and renal failure. Fakhouri F; Guerraoui H; Presne C; Peltier J; Delarue R; Muret P; Knebelmann B Br J Haematol; 2004 Apr; 125(1):96-7. PubMed ID: 15015981 [No Abstract] [Full Text] [Related]
4. [Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis]. Kida M; Hirao M; Iizuka H; Hangaishi A; Usuki K Rinsho Ketsueki; 2016; 57(11):2339-2344. PubMed ID: 27941283 [TBL] [Abstract][Full Text] [Related]
5. [Desensitization to lenalidomide]. Cañamares Orbis I; García Muñoz C; Cortijo Cascajares S; Méndez Esteban ME Farm Hosp; 2012; 36(6):542-3. PubMed ID: 23461448 [No Abstract] [Full Text] [Related]
8. Maintenance therapy for multiple myeloma. McCarthy PL; Palumbo A Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886 [TBL] [Abstract][Full Text] [Related]
9. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. Dasanu CA; Bockorny B; Alexandrescu DT J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794 [TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma: is a shift toward continuous therapy needed to move forward? Guglielmelli T; Palumbo A Expert Rev Hematol; 2015 Jun; 8(3):253-6. PubMed ID: 25582032 [TBL] [Abstract][Full Text] [Related]
11. Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. Cheah CY; Orlowski RZ; Manasanch EE; Oo TH Ann Hematol; 2015 Sep; 94(9):1605-7. PubMed ID: 26044891 [No Abstract] [Full Text] [Related]
12. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment. João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; Esteves S; Esteves GV Ann Hematol; 2016 May; 95(6):931-6. PubMed ID: 27068406 [TBL] [Abstract][Full Text] [Related]
13. Thalidomide and lenalidomide in the treatment of multiple myeloma. Kumar S; Rajkumar SV Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621 [TBL] [Abstract][Full Text] [Related]
14. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916 [TBL] [Abstract][Full Text] [Related]
15. A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients. Shida S; Takahashi N; Miura M; Niioka T; Matsumoto M; Hagihara M; Kobayashi T; Abumiya M; Kameoka Y; Fujishima N; Tagawa H; Hirokawa M; Sawada K Ther Drug Monit; 2014 Aug; 36(4):505-9. PubMed ID: 24562046 [TBL] [Abstract][Full Text] [Related]
16. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. de la Rubia J; Roig M; Ibáñez A; García I; Vera JA; Aguilar C; del Campo R; González N; Martínez R; Palomera L; Picón I; Rodríguez JN; Sanz MA Eur J Haematol; 2010 Oct; 85(4):363-5. PubMed ID: 20662900 [No Abstract] [Full Text] [Related]
17. Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma. Brissot E; Clavert A; Blin N; Roland V; Guillaume T; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Gaugler B; Moreau P; Mohty M Leukemia; 2015 Oct; 29(10):2098-100. PubMed ID: 25748683 [No Abstract] [Full Text] [Related]
18. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Kröger N; Zabelina T; Klyuchnikov E; Kropff M; Pflüger KH; Burchert A; Stübig T; Wolschke C; Ayuk F; Hildebrandt Y; Bacher U; Badbaran A; Schilling G; Hansen T; Atanackovic D; Zander AR Bone Marrow Transplant; 2013 Mar; 48(3):403-7. PubMed ID: 22863722 [TBL] [Abstract][Full Text] [Related]
19. [New strategy for the treatment of multiple myeloma]. Murakami H Rinsho Ketsueki; 2005 Dec; 46(12):1263-72. PubMed ID: 16447798 [No Abstract] [Full Text] [Related]
20. Sporadic late-onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone. Montagnese F; Portaro S; Musumeci O; Migliorato A; Moggio M; Fagiolari G; Rodolico C Muscle Nerve; 2015 Jun; 51(6):934-5. PubMed ID: 25524603 [No Abstract] [Full Text] [Related] [Next] [New Search]